Federated Hermes’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,410
| Closed | -$30.5K | – | 2152 |
|
|
2026
Q1 | $30.5K | Sell |
1,410
-21,809
| -94% | -$471K | ﹤0.01% | 1738 |
|
|
2025
Q4 | $553K | Buy |
23,219
+21,648
| +1,378% | +$442K | ﹤0.01% | 1281 |
|
|
2025
Q3 | $21.4K | Sell |
1,571
-138
| -8% | -$1.44K | ﹤0.01% | 1797 |
|
|
2025
Q2 | $13.9K | Sell |
1,709
-434
| -20% | -$3.71K | ﹤0.01% | 1765 |
|
|
2025
Q1 | $16.8K | Sell |
2,143
-750
| -26% | -$8.7K | ﹤0.01% | 1750 |
|
|
2024
Q4 | $43.1K | Sell |
2,893
-285
| -9% | -$4.65K | ﹤0.01% | 1707 |
|
|
2024
Q3 | $48.6K | Buy |
+3,178
| New | +$50.1K | ﹤0.01% | 1668 |
|
|
2023
Q4 | – | Sell |
-1,095
| Closed | -$19.7K | – | 2179 |
|
|
2023
Q3 | $19.7K | Sell |
1,095
-38,273
| -97% | -$769K | ﹤0.01% | 1766 |
|
|
2023
Q2 | $800K | Buy |
39,368
+34,915
| +784% | +$665K | ﹤0.01% | 1210 |
|
|
2023
Q1 | $81.2K | Buy |
4,453
+2,203
| +98% | +$42.1K | ﹤0.01% | 1690 |
|
|
2022
Q4 | $46.5K | Buy |
2,250
+126
| +6% | +$3.47K | ﹤0.01% | 1722 |
|
|
2022
Q3 | $56K | Buy |
+2,124
| New | +$56.2K | ﹤0.01% | 1658 |
|
|
2022
Q2 | – | Sell |
-3,541
| Closed | -$111K | – | 2255 |
|
|
2022
Q1 | $111K | Sell |
3,541
-10,137
| -74% | -$340K | ﹤0.01% | 1651 |
|
|
2021
Q4 | $553K | Buy |
13,678
+8,205
| +150% | +$318K | ﹤0.01% | 1456 |
|
|
2021
Q3 | $191K | Buy |
5,473
+5,217
| +2,038% | +$162K | ﹤0.01% | 1669 |
|
|
2021
Q2 | $7K | Sell |
256
-189,137
| -100% | -$5.4M | ﹤0.01% | 2012 |
|
|
2021
Q1 | $5.32M | Buy |
189,393
+188,881
| +36,891% | +$6.57M | 0.01% | 837 |
|
|
2020
Q4 | $13K | Sell |
512
-116,773
| -100% | -$2.83M | ﹤0.01% | 1951 |
|
|
2020
Q3 | $2.01M | Buy |
117,285
+65,060
| +125% | +$1.45M | ﹤0.01% | 986 |
|
|
2020
Q2 | $1.29M | Sell |
52,225
-45,182
| -46% | -$1.22M | ﹤0.01% | 1157 |
|
|
2020
Q1 | $1.35M | Buy |
97,407
+91,309
| +1,497% | +$1.14M | ﹤0.01% | 1016 |
|
|
2019
Q4 | $62K | Sell |
6,098
-407
| -6% | -$3.42K | ﹤0.01% | 1720 |
|
|
2019
Q3 | $59K | Sell |
6,505
-82
| -1% | -$659 | ﹤0.01% | 1706 |
|
|
2019
Q2 | $53K | Buy |
6,587
+840
| +15% | +$8.41K | ﹤0.01% | 1668 |
|
|
2019
Q1 | $72K | Buy |
5,747
+2,038
| +55% | +$22.1K | ﹤0.01% | 1623 |
|
|
2018
Q4 | $40K | Sell |
3,709
-232
| -6% | -$2.71K | ﹤0.01% | 1683 |
|
|
2018
Q3 | $55K | Buy |
+3,941
| New | +$50.3K | ﹤0.01% | 1726 |
|
Other funds holding RCUS
GS
SCM
WP
Federated Hermes's RCUS Position: Q2 2026 in Review
Federated Hermes sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 1,410 shares — an estimated $30.5K sold.
Federated Hermes first reported a position in RCUS in Q3 2018 and held it in 27 quarters. The position peaked at $5.32M in Q1 2021. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Federated Hermes reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
- Federated Hermes sold 1,410 Arcus Biosciences shares in Q2 2026, an estimated $30.5K.
- Federated Hermes first reported a position in Arcus Biosciences in Q3 2018 and held it in 27 quarters.
- Federated Hermes's Arcus Biosciences position peaked at $5.32M in Q1 2021.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.